* CohBar Inc CWBR.OQ CWBR.O is expected to show no
change in
quarterly revenue when it reports results on November 8.
*
* Refinitiv's mean analyst estimate for CohBar Inc is for a
loss
of $1.02 per share.
* The one available analyst rating on the shares is "buy".
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".
* Wall Street's median 12-month price target for CohBar Inc
is
$18, above its last closing price of $2.19.
This summary was machine generated November 5 at 00:04 GMT. All
figures in US dollars unless otherwise stated